Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05627245 · ClinicalTrials.gov registry record · Phase 1
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
A Phase 1 study of Recurrent Follicular Lymphoma and Refractory B-Cell Non-Hodgkin Lymphoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 11
- Study locations
NCT05627245 is a Phase 1 study of Recurrent Follicular Lymphoma and Refractory B-Cell Non-Hodgkin Lymphoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 48 participants, above the 31-participant average among 20 other Recurrent Follicular Lymphoma trials with a reported enrollment target (55% higher). The trial reports 11 study locations across 9 states.
The verdict
NCT05627245, a Phase 1 study of Recurrent Follicular Lymphoma and Refractory B-Cell Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 11
- Study locations
Study Summary
This phase I trial tests the safety, side effects, and best dose of combination therapy with tazemetostat and belinostat in treating patients with lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Tazemetostat is in a class of medications called EZH2 inhibitors. The EZH2 gene provides instructions for making a type of enzyme called histone methyltransferase which is involved in gene expression and cell division. Blocking EZH2 may help keep cancer cells from growing. Belinostat is in a class of medications called histone deacetylase inhibitors. Histone deacetylases are enzymes needed for cell division. Belinostat may kill cancer cells by blocking histone deacetylase. It may also prevent the growth of new blood vessels that tumors need to grow and may help make cancer cells easier to kill with other anticancer drugs. There is some evidence in animals and in living human cells that combination therapy with tazemetostat and belinostat can shrink or stabilize cancer, but it is not known whether this will happen in people. This trial may help doctors learn more about treatment of patients with relapsed or refractory lymphoma.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy Procedure
- DRUG Belinostat
- OTHER Pharmacokinetic Study
Study Locations (11)
Kansas
- University of Kansas Clinical Research Center - Fairway
- University of Kansas Cancer Center - Kansas City
- University of Kansas Hospital-Westwood Cancer Center - Westwood
California
- University of California Davis Comprehensive Cancer Center - Sacramento
Connecticut
- Yale University - New Haven
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center - New York
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Utah
- Huntsman Cancer Institute/University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05627245
The ClinicalTrials.gov registry entry for NCT05627245 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 31-participant average among 20 other Recurrent Follicular Lymphoma trials with a reported enrollment target (55% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Follicular Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05627245 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Kansas, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05627245 about?
NCT05627245 is a clinical study titled "Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment". This phase I trial tests the safety, side effects, and best dose of combination therapy with tazemetostat and belinostat in treating patients with lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Tazemetostat is in a class of me...
What is the current status of trial NCT05627245?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-03-01. Estimated completion is 2026-09-01.
What conditions does trial NCT05627245 study?
This clinical trial studies the following conditions: Recurrent Follicular Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma.
What interventions are being tested in trial NCT05627245?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), Belinostat (DRUG), Pharmacokinetic Study (OTHER).
Who is sponsoring clinical trial NCT05627245?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05627245 being conducted?
This trial has 11 study locations across California, Connecticut, Kansas, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Q702 for the Treatment of Patients With Hematologic Malignancies
RECRUITING · Phase 1
-
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
RECRUITING · Phase 1
-
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Recurrent Follicular Lymphoma
All registered trials for this condition
Refractory B-Cell Non-Hodgkin Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.